spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

SGS Enrolls First Patient into Biophytis’ COVA Clinical Study, a COVID-19 Clinical Trial

SGS

SGS is pleased to announce the enrolment of the first patient into an important new clinical trial designed to examine the safety, tolerability, and efficacy of a potential drug candidate for people suffering with COVID-19 related respiratory failure



SGS was chosen by French biotech company Biophytis to conduct its COVA study – a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure. The study, which has so-far received regulatory approval in Belgium, France, Brazil, the UK, and US, will initially recruit around 50 patients who have tested positive for COVID-19 and have also developed severe respiratory symptoms in the previous seven days. They must have obvious COVID-19 symptoms – e.g. pneumonia and oxygen distress – but cannot have been reliant on high-flow oxygen use or assisted ventilation during the previous 28-days.

Steven Thys, SGS’s Director of Global Clinical Operations commented: “As the whole world faces up to the challenge of finding effective treatments for COVID-19 we are pleased to announce the first patient has been successfully enrolled into the COVA Study. In the coming weeks, we may see more patients entering the study as more sites from different countries will join the study.

“Biophytis’ decision to choose SGS as its partner in the COVA Study is testament to our considerable expertise as a contract research organization with proficiency in the field of infectious diseases. Together, we have worked intensively to set up this study in a remarkably efficient timeframe.”

At the end of this initial 28-day trial, an Independent Data Monitoring Committee (IDMC) will conduct an interim analysis to determine whether the study should progress. The second phase could involve the recruitment of a further 260 patients. Totaling 310 patients participating in the trial.

About SGS Clinical Research Services

SGS Clinical Research is a leading contract research organization (CRO) with over 35 years of experience in clinical research and bioanalytical testing. Able to offer phase I to IV clinical trials, they have considerable experience with infectious diseases, respiratory disease, and vaccines.

SGS Clinical Research supports leading biotech and pharmaceutical companies in the design and conduct of clinical studies. By leveraging its global network of experts and clinical trial centers, SGS can optimize timelines and support study submissions, all in accordance with regulatory conditions.

For further information, please contact:

Steven Thys Director, Global Clinical Operations, SGS
T: +32 15 27 32 45
 
www.sgs.com/lifescience

About Biophytis SA

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.
phone +41 22 739 91 11
web sgs.com/
email 1 Place des Alpes P.O. Box 2152 1211 Geneva 1 Switzerland
 
Print this page
Send to a friend
   
spacer
News and Press Releases

IONTAS announces a new collaboration to identify novel immunotherapy targets

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
More info >>


White Papers

Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement